Takeda(TKPHF)

TOKYO, JapanPharmaceutical1 H-1B visas (FY2023)

Focus: Takeda is a Tokyo-based multinational pharmaceutical company with 49,000 employees specializing in small molecules and enzymes across gastroenterology, rare diseases, neuroscience, and oncology. It is one of the world's largest pharmaceutical companies by headcount and revenue scale.

GI/Gastroenterology Rare Diseases Neuroscience Oncology

Profile data last refreshed 38m ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

49,000

Open Jobs

1557+742 this month

Hot — 2224 jobs added in 30d

Net +742 (2224 new, 1482 removed). Aggressive expansion phase.

5 recent layoff filings (12 mo) — 637 affected

3/25/2026 — Cambridge, MA · 247 affected · Layoff
3/25/2026 — Cambridge, MA · 247 affected · Layoff
1/15/2026 — Cambridge, MA · 3 affected · Layoff
+2 more

Source: state DOL filings via Big Local News

Should You Work at Takeda?

AI assessment

Takeda offers a stable Big Pharma foundation with strong current franchises and global reach, but the looming patent cliff (2028–2029) combined with recent layoffs signal near-term restructuring risk; best suited for candidates seeking established-market expertise rather than long-term growth trajectory.

Why Work Here

Access to a diversified portfolio including peak-revenue franchises (TRINTELLIX $390M, NINLARO $312M) with patent exclusivity extending to 2029–2033, providing medium-term pipeline stability.

Data completeness

6/9 — Partial

Company HealthWatch

Pipeline

Early-stage

50 total

LOE Risk

2 imminent

ACTOPLUS MET XR

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

TRINTELLIX

Major Depressive Disorder

$390M

Peak6.3yr

Takeda's largest single revenue contributor (26% of revenue), providing a stable cash stream until patent expiry in 2032.

Help build intelligence for Takeda

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Engineering and R&D are actively hiring (49 and 38 open roles respectively), signaling investment in drug discovery and development infrastructure across rare diseases and oncology.

Global scale and Japanese parent company backing offer career mobility across therapeutic areas with established manufacturing, regulatory, and commercial infrastructure.

Watch Out For

Significant patent cliff risk: NINLARO ($312M) and MOTEGRITY ($62M) face LOE by 2029–2028, totaling $374M in revenue exposure with limited late-stage pipeline depth to replace lost exclusivity.
Recurring layoff activity across Cambridge, MA site: 250+ employees affected in 2025–2026 (including 247-person cuts in March 2026), plus 324-person California closure in 2024, suggesting ongoing restructuring and R&D consolidation.

Generated by Claude from Takeda's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NINLARO

Relapsed/Refractory Multiple Myeloma

$312M

Peak3.4yr

Second-largest revenue driver; faces patent cliff in 2029, exposing the company to significant revenue erosion in the medium term.

VYVANSE

ADHD and Binge Eating Disorder

$139M

Peak

Established neuroscience franchise supporting revenue, though lifecycle stage and patent data indicate no defined expiration in dataset.

ICLUSIG

Chronic Myeloid Leukemia

$123M

Peak7.5yr

Oncology franchise with patent protection until 2033, contributing meaningfully to specialty pharma positioning.

ENTYVIO

Ulcerative Colitis and Crohn's Disease

$100M

Growth

Recent FDA expansion approval for intravenous formulation (June 2026) positions this GI franchise as a growth driver; 16.99M shares granted June 2026 suggest company confidence.

DEXILANT

Gastroesophageal Reflux Disease

$87M

Peak5.7yr

GI market mainstay with patent protection until 2032, contributing to Takeda's gastroenterology portfolio depth.

MOTEGRITY

Chronic Idiopathic Constipation

$62M

Peak2.1yr

GI-focused product facing patent expiration in 2028, making it a near-term cliff risk requiring pipeline replacement.

FIRAZYR

Hereditary Angioedema

$56M

Peak

Rare disease franchise supporting niche indication; lifecycle and patent data indicate no defined expiration in dataset.

Pipeline & Clinical Trials

90Second IBD

IBD

N/A

Clinical Trials (1)

NCT0568613590Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients

N/A

Pen and Paper Digit Symbol Substitution Test

Major Depressive Episode

N/A

Freeze-dried live attenuated measles and rubella combined vaccine

Measles/Rubella

N/A

Clinical Trials (2)

NCT02151773Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination

N/A

NCT02158364Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination

A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insuff

Chronic Adrenal Insufficiency

N/A

Clinical Trials (1)

NCT01661387A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)

N/A

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Angioedemas, Hereditary

N/A

Clinical Trials (1)

NCT04955964A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

N/A

Recombinant ADAMTS13

Thrombotic Thrombocytopenic Purpura (TTP)

N/A

Clinical Trials (2)

NCT07429942A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program

N/A

NCT06441578A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

A Study on Vonoprazan in the Real-world Clinical Practice in China

Esophagitis Peptic

N/A

Clinical Trials (1)

NCT04501627A Study on Vonoprazan in the Real-world Clinical Practice in China

N/A

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

Portable EEG Device

Healthy Volunteers

N/A

Clinical Trials (1)

NCT04445129Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants

N/A

Technochrom C1-INH Kit

Hereditary Angioedema (HAE)

N/A

Clinical Trials (1)

NCT07293364A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema

N/A

non-interventional retrospective epidemiological observational study

Secondary Immunodeficiencies (SID)

N/A

Clinical Trials (1)

NCT04172467Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients

N/A

No intervention

Hereditary Angioedema (HAE)

N/A

Clinical Trials (5)

NCT05442567A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Phase 3

NCT06405087A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

Hereditary Angioedema (HAE)

N/A

Clinical Trials (1)

NCT03845400A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

N/A

No Intervention

Carcinoma, Non-Small-Cell Lung

N/A

Clinical Trials (1)

NCT04887519A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

N/A

Effect of Stimulant Medication on Loss of Control Eating in Youth With Attention Deficit/Hyperactivi

Loss of Control Eating

N/A

Clinical Trials (1)

NCT05592119Effect of Stimulant Medication on Loss of Control Eating in Youth With Attention Deficit/Hyperactivity Disorder

N/A

LITMUS Imaging Study

NAFLD

N/A

No Intervention

Mucopolysaccharidosis (MPS)

N/A

Clinical Trials (1)

NCT05155488A Study to Improve the Awareness of Mucopolysaccharidosis Type II in Brazil

N/A

low-fat diet

Insulin Resistance

N/A

Clinical Trials (1)

NCT00457938Novel Therapies for Metabolic Complications of Lipodystrophies

N/A

assessment

Sanfilippo Syndrome Type A

N/A

Clinical Trials (5)

NCT01112982An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.

Phase 4

NCT00336219Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)

TAK-881

Primary Immunodeficiency Diseases (PIDD)

N/A

Clinical Trials (5)

NCT06076642A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Phase 3

NCT06747351A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CUVITRU

Primary Immunodeficiency Diseases (PID)

N/A

Clinical Trials (4)

NCT03116347Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Phase 4

NCT05764993Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe In

Colitis, Ulcerative

N/A

Clinical Trials (1)

NCT03532932A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice

N/A

Diagnosis of SPAD using immunization with PPV23

Specific Antibody Deficiency

N/A

Clinical Trials (1)

NCT05664035Frequency of SPAD in Adult Patients

N/A

No Intervention

Celiac Disease

N/A

Clinical Trials (1)

NCT05309330Virtual Celiac Symptoms Study in Adults and Teenagers

N/A

Vonoprazan

A History of Gastric or Duodenal Ulcers

N/A

Clinical Trials (5)

NCT03116841Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation

Phase 4

NCT02037477Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Natural History Study of Children With Metachromatic Leukodystrophy

Lipid Metabolism Disorders

N/A

Clinical Trials (1)

NCT01963650Natural History Study of Children With Metachromatic Leukodystrophy

N/A

TachoSil®

Lymph Node Resection

N/A

Clinical Trials (2)

NCT01500135Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Phase 3

NCT01920958Use of Tachosil® for Lymph Sealing During Surgery

Virtual-reality

Hemophilia

N/A

Clinical Trials (1)

NCT05437211A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions

N/A

Esophageal dilation

Suspected Eosinophilic Esophagitis

N/A

Clinical Trials (1)

NCT00880906Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis

N/A

Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam

All Individuals Who Have Received at Least One Dose of TAK-003 (Qdenga) Dengue Vaccine

N/A

Clinical Trials (1)

NCT07501793Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam

N/A

Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease

Gastroesophageal Reflux

N/A

Clinical Trials (1)

NCT01167543Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease

N/A

Maralixibat

Alagille Syndrome (ALGS)

N/A

Clinical Trials (1)

NCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

N/A

Anti-TNF Therapy

Colitis, Ulcerative

N/A

Clinical Trials (1)

NCT03090139Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

N/A

Voglibose

Impaired Glucose Tolerance

N/A

Clinical Trials (1)

NCT01993927Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"

N/A

A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Tre

Von Willebrand Disease (VWD)

N/A

Clinical Trials (1)

NCT05265078A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi

N/A

Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Un

Stress Ulcer Prophylaxis

N/A

Clinical Trials (1)

NCT00919152Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU)

N/A

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants

Cytomegalovirus (CMV)

N/A

Clinical Trials (1)

NCT05576805A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada

N/A

Care bundle of active management

Cerebral Hemorrhage

N/A

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

Hemophilia

N/A

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT)

Cytomegalovirus (CMV)

N/A

Clinical Trials (1)

NCT05571137A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada

N/A

Confirmatory Testing

Acid Sphingomyelinase Deficiency

N/A

DXA scan + MRI

Bone Mineral Density

N/A

Clinical Trials (1)

NCT01460147Osteoporosis and MRI Study in Hemophilia

N/A

BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population

Plaque

N/A

Colonoscopy

N/A

Clinical Trials (2)

NCT00645801Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation

Phase 4

NCT00611442Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy

N/A

ATHN 9: Severe VWD Natural History Study

Von Willebrand Diseases

N/A

Clinical Trials (1)

NCT03853486ATHN 9: Severe VWD Natural History Study

N/A

Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age

Gastroesophageal Reflux

N/A

Clinical Trials (1)

NCT01048840Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age

N/A

Permeability measurement

Intestinal Diseases

N/A

Clinical Trials (1)

NCT02246647Biomarkers for Intestinal Permeability in Patients With Constipation

N/A

Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical

Mucopolysaccharidosis (MPS)

N/A

Clinical Trials (1)

NCT02095015Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)

N/A

TAK-577

Von Willebrand Disease (VWD)

N/A

Clinical Trials (1)

NCT06173024Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

N/A

Inflammatory Bowel Disease in South Eastern Norway

Colitis, Ulcerative

N/A

Clinical Trials (1)

NCT02727959Inflammatory Bowel Disease in South Eastern Norway

N/A

Interview Prep Quick Facts

Portfolio: 94 approved products, 164 clinical trials

Top TAs: Oncology, Metabolic Diseases, Immunology

H-1B (2023): 1 approval

Publications: 93 in PubMed

Open Roles: 1557 active jobs

Portfolio Health

Pre-Launch5 (5%)

Growth4 (4%)

Peak17 (18%)

LOE Approaching48 (51%)

Post-LOE20 (21%)

94 total products

Therapeutic Area Focus

Oncology

11 marketed299 pipeline

Metabolic Diseases

27 marketed167 pipeline

Immunology

6 marketed148 pipeline

Rare Diseases

3 marketed110 pipeline

Hiring Trend

Actively Hiring

1557

Open Roles

+618

Added

-310

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (8)

2026-03-25

247 employees affected— Cambridge, MA

2026-03-25

247 employees affected— Cambridge, MA

2026-01-15

3 employees affected— Cambridge, MA

2026-01-15

3 employees affected— Cambridge, MA

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment.

Journal of medical economics

2026

PMID:41811308

Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis.

PIOGLITAZONE HYDROCHLORIDE

pioglitazone

Post-LOE

ORAL · TABLET

action. Pioglitazone hydrochloride decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism. In animal models of diabetes, pioglitazone reduces the hyperglycemia, hyperinsulinemia, and hypertriglyceridemia characteristic of insulin-resistant states such as type 2 diabetes. The metabolic changes produced by pioglitazone result in increased responsiveness of insulin-dependent tissues and are observed in numerous animal models of insulin resistance. Because pioglitazone enhances the effects of circulating insulin (by decreasing insulin resistance), it does not lower blood glucose in animal models that lack endogenous insulin.

2013

NCT02528786Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study

Phase 1

NCT03763162Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

NCT05755035A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Phase 2/3

NCT04636502Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID)

N/A

NCT02388737Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis

Phase 3

13 marketed83 pipeline

Cardiovascular

10 marketed72 pipeline

Neurology

5 marketed76 pipeline

Nephrology

5 marketed45 pipeline

137 employees affected— Cambridge, MA

2025-10-01

137 employees affected— Cambridge, MA

2024-05-09

324 employees affected— CA

2024-01-31

— Cambridge, MA

Source: state DOL filings, aggregated via Big Local News

Three major workforce reductions in 2024–2026: 324-person CA facility closure (May 2024), 137-person Cambridge cut (October 2025), and 247-person Cambridge layoff (January–March 2026), totaling 708+ affected employees and signaling aggressive portfolio/site consolidation.

Cambridge-based R&D roles face significant attrition risk; restructuring appears tied to pipeline deprioritization ahead of patent cliffs; candidates should clarify program viability and site stability during interviews.

Journal of medical economics

2026

PMID:41823988

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Takeda(TKPHF)

Should You Work at Takeda?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (32)

Key Products by Revenue

Other Products (8)

Pipeline & Clinical Trials

Recent News · Takeda(10)

Open Jobs (1557)

Head, R&D Automation Platform

Associate Director of HCP Branded Strategy and Marketing

Head Counsel, Global Transactions & Contracts Legal – Commercial

Senior Product Manager, IBD Consumer Marketing

Promotional Review Team Ops Analyst, FTP/Neuro

Plasma Nurse-LPN

Plasma Center Paramedic – EMT-P

Biolife - Practical Nurse

Plasma Center Nurse- LPN

Associate Director, Head of IMP Quality

Specialty Business Manager, IBD - Brooklyn, NY (Manhattan, Brooklyn and Staten Island)

Specialty Business Manager, Derm - Miami N, FL

Director, Project Management – Lab Automation & Transformation

Plasma Center Senior Technician

Medical Screener - Bilingual

Head of Global Regulatory Affairs, Oncology

Head Counsel, Global Transactions & Contracts Legal – DD&T and BP

Head Counsel, Global Transactions & Contracts Legal – Global Supply & Quality

Entry Level Phlebotomy

Senior Plasma Center Technician

Plasma Center Technician

Plasma Center Supervisor

Senior Manager, FTP Analytics

Medical Support Specialist

Plasma Center Nurse - RN

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (8)

Research Publications(10)